NCT00100165View on ClinicalTrials.gov

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

Placebo

Placebo by mouth twice a day for 4 weeks

DRUG

3-(2,4 dimethoxybenzylidene anabaseine) 150 mg

3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks

DRUG

3-(2,4 dimethoxybenzylidene anabaseine) 75 mg

3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks

Trial Locations (1)

80220

VA Eastern Colorado Health Care System, Denver, CO, Denver

All Listed Sponsors
collaborator

VA Office of Research and Development

FED

lead

University of Colorado, Denver

OTHER

NCT00100165 - Phase 2 Trial of a Nicotinic Agonist in Schizophrenia | Biotech Hunter | Biotech Hunter